Edit Organization: Dana–Farber Cancer Institute

Organization Name:	Toggle options
Organization Type:	Toggle options Administrative agencies Administrative and Support Agencies Administrative and Support Agencies (Sub-organization) Administrative and Support Agency Advisory Commission Advocacy Groups Army Branch Boards, Commissions, and Committees Boards, Commissions, and Committees (Sub-organization) Co-operatives Commissions Commissions and Committees Committees, Boards, and Commissions Congressional Committee Congressional Office Courts Cultural Institutions Cultural Institutions (Sub-organization) Cultural Institutions; Public-Private Partnerships Educational Institution Educational Institution (Sub-organization) Educational Program Executive agency Executive department Executive Departments Executive Departments (Sub-organization) Executive Departments; Research and Development Agencies Federal agency Federal Law Enforcement Agency Federal Shared Services Organization Government Government (Disbanded) Government (Military) Government Advisory Government Agency Government Agency/Digital Consultancy Government Agency/Educational Institution Government Agency/Military Command Government Agency/Research Lab Government Committee Government Corporation Government Corporations Government Corporations (Sub-organization) Government Corporations, Administrative and Support Agencies Government Mechanism Government Program Government-Sponsored Enterprises (GSEs) Independent Agencies Independent Agencies (Sub-organization) Independent Agencies; Foundations Independent Agency Intelligence Agencies Intelligence Agencies (Sub-organization) Intelligence Agency Intelligence Coordination Agency International Organizations Judicial Branch Judicial Branch (Specific Court) Law Enforcement Agency Law Enforcement Agency (Defunct) Legislative Branch Military Command Military Intelligence and Technology Unit Military Intelligence Facility Military Intelligence Unit Military Law Enforcement and Security Force Military Occupational Specialty Military Reserve Force Military Security Component Non-Governmental Organizations (NGOs); Educational Institution Non-profit Non-profit (Charitable Organization) Non-profit (Research and Development Agencies) Non-profit (Sub-organization) Non-profit, Non-Governmental Organizations (NGOs), International Organizations Nonprofit Organization Numbered Air Force Professional Association Professional Societies Programs (within a Government Agency) Public-Private Partnerships Public-Private Partnerships; Executive Departments Public-Private Partnerships; Think Tanks Regional Commissions Regulatory Commission Regulatory Commissions Regulatory Commissions; Executive Departments Research and Development Agencies Research and Development Agencies (Sub-organization) Research and Development Agencies; Educational Institution Research and Development Agency Research and Development Facility Research Program Security Force Service Organizations State and Local Government Agencies (Sub-organization) Trade Associations Uniformed service Volunteer Civilian Organization
Mission:	Dana–Farber provides expert cancer care, advancing treatment and prevention through research for global patients.
Parent Organization:	Toggle options
Top Organization:	Toggle options Advocate Health Agency for Global Media Air Education and Training Command Air University Central Intelligence Agency Commodity Futures Trading Commission Congress Consumer Financial Protection Bureau Consumer Goods Forum Department of Agriculture Department of Agriculture; Tufts University Department of Atomic Energy Department of Commerce Department of Defense Department of Defense and German Ministry of Defense Department of Defense, under the Office of the Under Secretary of Defense for Research and Engineering Department of Defense; U.S. Department of Health and Human Services; U.S. Department of Agriculture; U.S. Department of Homeland Security Department of Education Department of Energy Department of Health and Human Services Department of Homeland Security Department of Housing and Urban Development Department of Justice Department of Labor Department of State Department of the Air Force Department of the Army Department of the Interior Department of the Interior (USGS) Department of the Interior and U.S. Department of Agriculture (Joint Operation) Department of the Navy Department of the Treasury Department of Transportation Department of Veterans Affairs Duke University Environmental Protection Agency Executive branch Executive Office of the President Farm Credit System Federal Communications Commission Federal Mediation and Conciliation Service Federal Trade Commission General Service Administration Geological Survey Georgia Institute of Technology Independent Agency International Energy Agency Judicial Conference of the United States National Academies National Aeronautics and Space Administration National Cancer Institute National Defense University National Endowment for the Arts National Institutes of Health National Oceanic and Atmospheric Administration National Science Foundation Office of Personnel Management Office of the Director of National Intelligence Partnership Post Office Space Force U.S. Agency for Global Media U.S. Department of Energy United States Air Force United States Congress United States Department of Agriculture United States Department of Health and Human Services United States Department of Transportation United States DOGE Service United States Government United States Intelligence Community Wildland Fire Leadership Council
Creation Legislation:	Toggle options Please enter 1 or more characters.
Employees:
Budget:
Organization Executive:	Toggle options
Services:	Adult cancer treatment; Pediatric cancer treatment; Cancer research; Clinical trials
Regulations:
Headquarters Location:	Calculate coordinates using address +− © OpenStreetMap contributors
Headquarters Address:
Website:
Wikipedia:

Free text:

{{Short description|Cancer treatment and research institution in Boston, US}} '''Dana–Farber Cancer Institute''' ('''DFCI''') is a comprehensive [[cancer]] treatment and research center in Boston, [[Massachusetts]]. Dana-Farber is the founding member of the Dana-Farber/Harvard Cancer Center, Harvard's [[Comprehensive Cancer Center]] designated by the [[National Cancer Institute]], and one of the 15 clinical affiliates and research institutes of [[Harvard Medical School]]. As of 2023, Dana-Farber is ranked the #4 cancer hospital in the world.<ref>{{Cite web |last=Newsweek |date=2022-09-14 |title=World's Best Specialized Hospitals 2023 |url=https://www.newsweek.com/rankings/worlds-best-specialized-hospitals-2023 |access-date=2023-01-02 |website=Newsweek |language=en}}</ref> Two [[Nobel Prize in Physiology or Medicine|Nobel laureates in Physiology or Medicine]] are among its past and present faculty. In 2024, an investigation revealed evidence of [[scientific misconduct|research misconduct]] in dozens of studies authored by Dana-Farber researchers, including then [[President (corporate title)|President]] and [[Chief executive officer|CEO]] [[Laurie Glimcher]], the [[Vice President|Executive Vice President]] and [[Chief operating officer|COO]], and the [[Scientific integrity|Research Integrity Officer]].<ref name="f918">{{cite web | last=Mueller | first=Benjamin | title=Dana-Farber Cancer Institute Seeks to Retract Flawed Studies | website=The New York Times | date=2024-01-22 | url=https://www.nytimes.com/2024/01/22/health/dana-farber-cancer-studies-retractions.html | access-date=2024-08-17}}</ref><ref name="i173">{{cite web | last=Wosen | first=Jonathan | last2=Chen | first2=Angus | title=Dana-Farber cancer researchers moving to retract one paper, correct others in broad investigation of manipulated data | website=BostonGlobe.com | date=2024-01-20 | url=https://www.bostonglobe.com/2024/01/19/business/dana-farber-cancer-data-manipulation/ | access-date=2024-08-17}}</ref><ref name="p658">{{cite web | last=Wosen | first=Jonathan | last2=Chen | first2=Angus | title=Dana-Farber cancer researchers moving to retract one paper, correct others in broad investigation of manipulated data | website=STAT | date=2024-01-19 | url=https://www.statnews.com/2024/01/19/dana-farber-cancer-institute-allegations-manipulated-data-glimcher/ | access-date=2024-08-17}}</ref> In response to these findings, Dana-Farber [[Retraction in academic publishing|retracted]] 7 papers<ref name="nbcnews.com">{{Cite web |date=2024-04-09 |title=Prestigious cancer research institute has retracted 7 studies amid controversy over errors |url=https://www.nbcnews.com/science/science-news/cancer-institute-dana-farber-retracts-studies-errors-rcna143922 |access-date=2024-11-14 |website=NBC News |language=en}}</ref> and corrected 31 others.<ref name="z912">{{cite web | last=Chen | first=Angus | title=Dana-Farber expands studies to be retracted to 6, plus 31 to be corrected over mishandled data | website=BostonGlobe.com | date=2024-01-22 | url=https://www.bostonglobe.com/2024/01/22/metro/dana-farber-expands-studies-be-retracted-6-plus-31-be-corrected-over-mishandled-data/ | access-date=2024-08-24}}</ref> In October 2024, [[Laurie Glimcher]] stepped down as President and CEO.<ref name="o622">{{cite web | last=Edelman | first=Larry | title=Dana-Farber CEO Laurie Glimcher to step down next month | website=BostonGlobe.com | date=2024-09-03 | url=https://www.bostonglobe.com/2024/09/03/business/dana-farber-glimcher-ebert-new-ceo/ | access-date=2024-10-12}}</ref> ==Overview== Dana–Farber employs more than 4,855 full-time and part-time workers, 529 faculty, and has annual gross revenues of about $1,733,386,000.<ref>{{cite web|url=https://www.dana-farber.org/uploadedFiles/Content/Promos/Three_Column/Publications/dana-farber-2019-facts.pdf|title=Dana-Farber Cancer Institute 2019 Facts|url-status=dead|archive-url=https://web.archive.org/web/20150717011625/http://www.dana-farber.org/uploadedFiles/Library/modules/dana-farber-2015-facts.pdf|archive-date=2015-07-17|access-date=2015-07-16}}</ref> All faculty and postdoctoral research fellows at Dana–Farber hold the equivalent academic positions concurrently at Harvard University. There are more than 523,425 adult and pediatric patient visits (combined exam and office visits) a year, and it is involved in more than 1,000 clinical trials. It is internationally known for its research and clinical excellence. Expertscape ranks its programs in aplastic anemia<ref name="rank_expertscapeaa">{{cite web|url=http://www.expertscape.com/leaders/aplastic+anemia |title=Expertscape: Aplastic Anemia, December 2013 |publisher=expertscape.com |date=December 2013 |access-date=2015-08-17}}</ref> and multiple myeloma<ref name="rank_expertscapemm">{{cite web|url=http://www.expertscape.com/leaders/multiple-myeloma |title=Expertscape: Multiple Myeloma, February 2014 |publisher=expertscape.com |date=February 2014 |access-date=2014-02-18 }}</ref> as best in the world. It has been also ranked overall the fifth best cancer hospital in the United States by ''[[U.S. News & World Report]]''.<ref>{{cite news|title=Best Hospitals Specialty Search: Cancer|work=[[U.S News & World Report]]|url=http://health.usnews.com/best-hospitals/rankings/cancer|access-date=2020-04-19|url-status=dead|archive-url=https://web.archive.org/web/20120406163531/http://health.usnews.com/best-hospitals/rankings/cancer|archive-date=2012-04-06}}</ref> Dana–Farber is a member of the [[Multiple Myeloma Research Consortium]]. In addition to being a principal teaching affiliate of Harvard Medical School, Dana–Farber is also a federally-designated Center for AIDS Research, and is a founding member of the Dana–Farber/Harvard Cancer Center (DF/HCC),<ref>{{cite web|url=http://www.dfhcc.harvard.edu/ |title=Dana-Farber/Harvard Cancer Center |access-date=2007-10-15}}</ref> a research consortium that is one of the 39 federally-designated [[Comprehensive Cancer Center]]s. Providing advanced training in cancer treatment and research for an international faculty, Dana–Farber conducts community-based programs in cancer prevention, detection, and control in New England, and maintains joint programs with other Boston institutions, including [[St. Elizabeth's Medical Center (Boston)|St. Elizabeth's Medical Center]], [[Brigham and Women's Hospital]], [[Boston Children's Hospital]], and [[Massachusetts General Hospital]]. Dana–Farber is supported by the [[National Cancer Institute]], the [[National Institute of Allergy and Infectious Diseases]], and private foundations and individuals contributions. [[The Jimmy Fund]] is the principal charity of the Institute named for one of its child patients. The [[Boston Red Sox]] adopted the Jimmy Fund as its official charity in 1953 and continues to prominently sponsor the charity.{{citation needed|date=June 2022}} [[Benjamin L. Ebert]] is President/CEO of Dana–Farber Cancer Institute.<ref name="o622">{{cite web |last=Edelman |first=Larry |date=2024-09-03 |title=Dana-Farber CEO Laurie Glimcher to step down next month |url=https://www.bostonglobe.com/2024/09/03/business/dana-farber-glimcher-ebert-new-ceo/ |access-date=2024-10-12 |website=BostonGlobe.com}}</ref> In 2015, ''[[Forbes]]'' listed the charity as the 37th biggest in the U.S.<ref>{{cite web|url=https://www.forbes.com/companies/dana-farber-cancer-institute/|title=Dana-Farber Cancer Institute on the Forbes The 100 Largest U.S. Charities List|website=Forbes|access-date=14 April 2018}}</ref> ==History== In 1947, [[Pediatrics|pediatric]] [[pathologist]] [[Sidney Farber]] founded the Children's Cancer Research Foundation (CCRF) with [[Variety, the Children's Charity|Variety Club]] to raise money for cancer research. The foundation launched the [[Jimmy Fund]] the following year with an advertising campaign featuring a child nicknamed "Jimmy",<ref name="MillerTribute">{{cite journal |author=Miller, D.R. |year=2006 |title=A tribute to Sidney Farber – the father of modern chemotherapy |journal=British Journal of Haematology |volume=134 |issue=1 |pages=20–26 |doi=10.1111/j.1365-2141.2006.06119.x |pmid=16803563 |s2cid=45434777 |doi-access=}}</ref> and constructed the Jimmy Fund Building in the [[Longwood Medical and Academic Area|Longwood Medical Area]] in 1952 to house research facilities.<ref name="milestones">{{Cite web |title=Milestones in the History of Dana-Farber and the Jimmy Fund {{!}} Dana-Farber Cancer Institute |url=https://www.dana-farber.org/about/history/timeline |access-date=2025-01-03 |website=www.dana-farber.org |language=en}}</ref> In 1969, the Foundation expanded their programs to include patients of all ages, and in 1974 was renamed the Sydney Farber Cancer Center.<ref name="milestones" /> In 1962, philanthropist [[Charles A. Dana (philanthropist)|Charles A. Dana]], through the [[Dana Foundation]], began financial support of the CCRF. The Dana Building was opened near the Jimmy Fund building in 1975,<ref>{{cite web |title=Richard A. and Susan F. Smith Research Laboratories |url=https://www.tutorperinibuilding.com/projects/healthcare/richard-a-and-susan-f-smith-research-laboratories/ |publisher=Tutor Perini |access-date=3 January 2025}}</ref> and, in 1983, the organization's name was changed to Dana–Farber Cancer Institute in recognition of the foundation's support.<ref name="MillerTribute" /> In 1997, the Smith Research Laboratories building was opened across the street from the Dana Building and the [[Inpatient care|inpatient hospital]] was moved to [[Brigham and Women's Hospital]], freeing up space for research, laboratories, and adult outpatient care.<ref name="milestones" /> The Yawkey Center for Cancer Care was opened adjacent to the Smith Laboratories in 2011 to provide additional outpatient facilities.<ref>{{Cite web |last=Ragusea |first=Adam |date=2011-01-05 |title=Dana Farber Introduces A New Weapon In The Cancer-Fighting Arsenal |url=https://www.wbur.org/radioboston/2011/01/05/yawkey-center |access-date=2025-01-03 |website=Radio Boston |publisher=WBUR |language=en}}</ref> In September 2023, Dana–Farber Cancer Institute announced a new partnership with [[Beth Israel Deaconess Medical Center]] and plans to build a new standalone inpatient hospital focused on treating adult cancer patients. This includes a departure from their current home and longtime affiliation with Brigham and Women's Hospital, which had been recognized among U.S. News & World Report's top cancer care facilities for 23 consecutive years.<ref>{{Cite web |last=Sacchetti |first=Sharman |date=2023-09-15 |title=New hospital proposed as Boston-based medical giants change partnerships |url=https://www.wcvb.com/article/dana-farber-beth-israel-deaconess-brigham-womens-boston-cancer-hospital/45141829 |access-date=2024-01-06 |website=WCVB |language=en-US}}</ref> ==Breakthroughs== Dana–Farber has a long history of breakthrough discoveries in cancer care and research. {{citation needed|date=June 2022}} * 1947: Sidney Farber leads a team of researchers who are the first in the world to attain temporary remissions of [[acute lymphocytic leukemia]], the most common cancer in children, using [[aminopterin]]. This, and another [[antifolate]] drug, [[methotrexate]] used by Dr. Farber, were discovered and supplied by Dr. [[Yellapragada Subba Rao]], Director, Research at Lederle Co. at Pearl River, NY. {{citation needed|date=June 2022}} * 1954: Farber and his colleagues achieve the first remissions of [[Wilms' tumor]], a common form of childhood cancer, and boost cure rates from 40 percent to 85 percent. {{More citations needed|date=October 2024}} * 1976: Researchers at the Sidney Farber Cancer Center (now Dana–Farber) develop a new treatment for [[acute myelogenous leukemia]] that produces the first complete remissions of the disease in up to half of all patients. {{citation needed|date=June 2022}} * 1978: Institute investigators develop combination chemotherapy for soft-tissue [[sarcoma]]s resulting in a 50-percent response rate. {{citation needed|date=June 2022}} * 1980: Dana–Farber president [[Baruj Benacerraf]] receives the [[Nobel Prize in Physiology or Medicine]] for the discovery of the [[major histocompatibility complex]], which enables the immune system to recognize [[antigens]]. {{citation needed|date=June 2022}} * 1982: Dana–Farber researchers develop and apply the [[CA-125]] blood test for [[ovarian cancer]]. They also are among the first to suspect a relationship between the retrovirus that causes [[Human T-lymphotropic virus 1|human T-cell leukemia]] (HTLV-1) and that which causes [[HIV/AIDS|AIDS]] ([[Subtypes of HIV|HIV-1]]). {{citation needed|date=June 2022}} * 1991: Dana–Farber investigators help introduce the use of naturally occurring [[growth hormone]]s following high-dose chemotherapy, making [[bone marrow transplantation]] safer and more effective. {{citation needed|date=June 2022}} * 1993: Dana–Farber investigators discover the gene that increases the risk for a common type of [[colon cancer]]. The [[DNA mismatch repair|''MSH2'']] gene and later the [[DNA mismatch repair|''MLH1'']] gene (also by DFCI investigators) are linked to hereditary nonpolyposis colorectal cancer ([[Hereditary nonpolyposis colorectal cancer|HNPCC]]). {{citation needed|date=June 2022}} * 1996: Institute researchers dramatically advance the understanding of how HIV, the virus that causes AIDS, replicates and infects healthy cells. ''Science'' magazine heralds this discovery as its "Breakthrough of the Year". {{citation needed|date=June 2022}} * 1998: A drug called [[imatinib]] (Gleevec), the early work for which was done at Dana–Farber {{citation needed|date=June 2022}}, achieves striking success in many patients with [[chronic myelogenous leukemia]]. {{citation needed|date=June 2022}} * 1999: Working with colleagues at other hospitals, Dana–Farber scientists begin the first human studies of [[endostatin]], one of a new generation of compounds that arrest or shrink tumors by shutting off their blood supply. {{citation needed|date=June 2022}} * 2002: Dana–Farber researchers find that Gleevec, a targeted therapy that achieved striking success against chronic myelogenous leukemia, can shrink and even eliminate tumors in some patients with a rare and otherwise incurable digestive-tract cancer called gastrointestinal stromal tumor. {{citation needed|date=June 2022}} * 2003: Scientists at Dana–Farber and the [[Whitehead Institute]] find a gene "signature" in several types of tumors that suggests they are likely to spread to other parts of the body, potentially leading to tests for determining whether tumors have the potential to metastasize. {{citation needed|date=June 2022}} * 2005: Dana–Farber scientists report that the drug [[gefitinib]] (Iressa) produces dramatic benefits in [[non-small cell lung cancer]] patients who carry an abnormal version of a key protein, a potentially life-saving discovery for tens of thousands of patients around the world every year. {{citation needed|date=June 2022}} * 2019: Dana–Farber physician and researcher [[William Kaelin Jr.]] receives the [[Nobel Prize in Physiology or Medicine]] for "discoveries of how cells sense and adapt to oxygen availability."<ref>{{cite web |title=William G. Kaelin Jr – Facts – 2019 |url=https://www.nobelprize.org/prizes/medicine/2019/kaelin/facts/ |website=NobelPrize.org |access-date=6 July 2022}}</ref> ==Academic integrity issues== In 2024, an investigation revealed evidence of [[scientific misconduct|research misconduct]] in dozens of studies authored by Dana-Farber researchers.<ref name="f918">{{cite web |last=Mueller |first=Benjamin |date=2024-01-22 |title=Dana-Farber Cancer Institute Seeks to Retract Flawed Studies |url=https://www.nytimes.com/2024/01/22/health/dana-farber-cancer-studies-retractions.html |access-date=2024-08-17 |website=The New York Times}}</ref><ref name="i173">{{cite web |last=Wosen |first=Jonathan |last2=Chen |first2=Angus |date=2024-01-20 |title=Dana-Farber cancer researchers moving to retract one paper, correct others in broad investigation of manipulated data |url=https://www.bostonglobe.com/2024/01/19/business/dana-farber-cancer-data-manipulation/ |access-date=2024-08-17 |website=BostonGlobe.com}}</ref><ref name="p658">{{cite web |last=Wosen |first=Jonathan |last2=Chen |first2=Angus |date=2024-01-19 |title=Dana-Farber cancer researchers moving to retract one paper, correct others in broad investigation of manipulated data |url=https://www.statnews.com/2024/01/19/dana-farber-cancer-institute-allegations-manipulated-data-glimcher/ |access-date=2024-08-17 |website=STAT}}</ref> Notable Dana-Farber employees tied to the misconduct allegations included then [[President (corporate title)|President]] and [[Chief executive officer|CEO]] [[Laurie Glimcher]], the [[Vice President|Executive Vice President]] and [[Chief operating officer|COO]] William C. Hahn, and the [[Scientific integrity|Research Integrity Officer]] Barrett Rollins.<ref name="f918" /> The misconduct involved image discrepancies, including duplications of blots, bands, and plots. A review of the allegations was complicated by the authors' inability to provide the original data from older papers, citing lab storage limitations. [[Elisabeth Bik]], a recognized expert in image manipulation who examined some of the images, refrained from speculating on whether the manipulation was intentional. However, she noted that a large volume of data issues in a scholar's work can be "very suggestive of an intention to mislead."<ref>{{Cite web |title=Dana-Farber Cancer Institute Researchers Accused of Manipulating Data {{!}} News {{!}} The Harvard Crimson |url=https://www.thecrimson.com/article/2024/1/12/dana-farber-research-misconduct-allegations/ |access-date=2024-11-14 |website=www.thecrimson.com}}</ref> Not all of the studies reported on required a correction or retraction. The Institute noted that, “The presence of image discrepancies in a paper is not evidence of an author's intent to deceive. That conclusion can only be drawn after a careful, fact-based examination which is an integral part of our response. Our experience is that errors are often unintentional and do not rise to the level of misconduct.” The corrections and retractions were part of a larger trend and use of AI in identifying image discrepancies and other issues from researchers, universities and research institutions around the world.<ref name=expands>{{Cite web |last=Chen |first=Angus |last2=Wosen |first2=Jonathan |date=2024-01-22 |title=Dana-Farber expands studies to be retracted to 6, plus 31 to be corrected over mishandled data |url=https://www.statnews.com/2024/01/22/dana-farber-research-retractions-corrections/ |access-date=2024-06-05 |website=STAT |language=en-US}}</ref><ref>{{Cite news |last=Subbaraman |first=Nidhi |title=Harvard Teaching Hospital Seeks Retraction of Six Papers by Top Researchers |url=https://www.wsj.com/health/dana-farber-harvard-retractions-corrections-ceo-laurie-glimcher-935636f5 |access-date=2024-06-05 |work=WSJ |language=en-US}}</ref> More than 51 studies, many of them decades old, were affected. Dana-Farber's Office of Research Integrity immediately began a review of the papers and when needed, submitted corrections and retractions to the medical journals. In total, 7 papers were retracted<ref name="nbcnews.com"/> and 31 others were corrected,<ref name="expands" /> and, in October 2024, Laurie Glimcher stepped down as President and CEO.<ref name="o622" /> ==Patient care== Dana–Farber/St. Elizabeth's Cancer Center (DF/SEMC) and Dana–Farber/Brigham and Women's Cancer Center (DF/BWCC) are collaborations between Dana–Farber Cancer Institute, [[St. Elizabeth's Medical Center (Boston)|St. Elizabeth's Medical Center]], and [[Brigham and Women's Hospital]] to care for adults with cancer. Dana–Farber provides outpatient services, while inpatient care is provided by St. Elizabeth's Medical Center and Brigham and Women's Hospital. DF/SEMC and DF/BWCC care for adult patients in more than a dozen specialized treatment centers.{{citation needed|date=June 2022}} Dana–Farber/Boston Children's Cancer and Blood Disorders Center is a more than 70-year-old partnership between [[Boston Children's Hospital]] and Dana–Farber Cancer Institute that delivers comprehensive care to children with and survivors of all types of childhood cancers. They also work with several other local New England organizations that share a similar vision, such as [[Take a Swing at Cancer]],<ref>{{cite web|url=http://www.takeaswing.org/|title=tasc14|website=tasc14|access-date=14 April 2018}}</ref> Angel's Hope, Childhood Cancer Lifeline of New Hampshire and Andrew's Helpful Hands. ==Dana–Farber/Harvard Cancer Center== The '''Dana–Farber/Harvard Cancer Center''' is the largest [[National Cancer Institute]] (NCI) designated [[Comprehensive Cancer Center]] in the nation. Founded in 1997, DF/HCC is an inter-institutional research enterprise that unites all of the cancer research efforts of the Harvard affiliated community. The primary goal of the Cancer Center is to encourage and promote collaborative interactions and translational research that will lead to new approaches to cancer prevention, diagnosis, and treatment.{{citation needed|date=June 2022}} DF/HCC is one of just 39 NCI designated Comprehensive Cancer Centers. Its members hail from the following institutions: [[Beth Israel Deaconess Medical Center]], [[Brigham and Women’s Hospital]], [[Boston Children's Hospital]], Dana–Farber Cancer Institute, [[Harvard Medical School]], [[Harvard School of Public Health]], [[Massachusetts General Hospital]], and [[St. Elizabeth's Medical Center (Boston)|St. Elizabeth's Medical Center]].<ref>{{cite web|title=NCI Cancer Centers Program|url=http://cancercenters.cancer.gov/cancer_centers/dfhcc.html|url-status=dead|accessdate=2007-06-07|archiveurl=https://web.archive.org/web/20080505040735/http://cancercenters.cancer.gov/cancer_centers/dfhcc.html|archivedate=2008-05-05}}</ref> ==References== {{Commons category|Dana–Farber Cancer Institute}} {{Reflist}} {{Hospitals in Massachusetts}} {{authority control}} {{DEFAULTSORT:Dana-Farber Cancer Institute}} [[Category:Cancer research organizations]] [[Category:Cancer organizations based in the United States]] [[Category:NCI-designated cancer centers]] [[Category:Medical research institutes in Massachusetts]] [[Category:Teaching hospitals in Massachusetts]] [[Category:Hospitals in Boston]] [[Category:Harvard Medical School]] [[Category:Hospitals established in 1947]] [[Category:Hospital buildings completed in 1947]]